Core Insights - The animal health sector experienced a 1.14% increase on September 15, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - BioShares (600201) closed at 8.82, up 7.17% with a trading volume of 624,100 shares and a turnover of 539 million yuan [1] - Dayu Biological (871970) closed at 11.50, up 6.09% with a trading volume of 124,300 shares and a turnover of 139 million yuan [1] - Other notable performers include: - Jinhai Biological (002688) at 7.20, up 3.00% [1] - Ruipu Biological (300119) at 21.98, up 1.76% [1] - Zhongmu Co. (600195) at 7.50, up 1.63% [1] Capital Flow - The animal health sector saw a net outflow of 25.577 million yuan from institutional investors, while retail investors contributed a net inflow of 6.5625 million yuan [2] - The capital flow for individual stocks indicates: - Jinhai Biological had a net inflow of 32.1651 million yuan from institutional investors [3] - Zhongmu Co. had a net inflow of 6.8986 million yuan from institutional investors [3] - Ruipu Biological experienced a net outflow of 1.1475 million yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.21% on September 12, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Individual Stock Performance - Shunlian Biological (688098) closed at 11.85, up 2.07% with a trading volume of 85,100 shares and a turnover of 99.05 million yuan [1] - KQ Biological (688526) closed at 18.63, up 0.70% with a trading volume of 19,700 shares and a turnover of 36.27 million yuan [1] - Huisheng Biological (300871) closed at 22.55, up 0.53% with a trading volume of 54,100 shares and a turnover of 122 million yuan [1] - Dayu Biological (871970) led the decline, closing at 10.73, down 3.85% with a trading volume of 76,600 shares and a turnover of 82.31 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 15.44 million yuan from institutional investors, while retail investors experienced a net outflow of 9.04 million yuan [2] - Speculative funds recorded a net inflow of 24.47 million yuan [2] Detailed Capital Flow for Selected Stocks - Shunlian Biological had a net inflow of 14.94 million yuan from institutional investors, but a net outflow of 21.09 million yuan from retail investors [3] - Huisheng Biological experienced a net outflow of 7.83 million yuan from institutional investors, while retail investors had a net inflow of 9.81 million yuan [3] - KQ Biological saw a net outflow of 1.73 million yuan from institutional investors, with a minor net inflow from retail investors [3]

Company Overview - Shenlian Bio is located in Minhang District, Shanghai, established on June 28, 2001, and listed on October 28, 2019. The company specializes in the research, production, and sales of veterinary biological products, with 99.24% of its main business revenue coming from this sector [1][2]. Financial Performance - As of June 30, Shenlian Bio reported a revenue of 122 million yuan for the first half of 2025, a year-on-year decrease of 3.68%. The net profit attributable to the parent company was -12.87 million yuan, showing a year-on-year increase of 62.71% [2]. - The company has cumulatively distributed 158 million yuan in dividends since its A-share listing, with 47.22 million yuan distributed over the past three years [3]. Stock Performance - On September 12, Shenlian Bio's stock price increased by 2.07%, reaching 11.85 yuan per share, with a trading volume of 76.35 million yuan and a turnover rate of 1.61%. The total market capitalization is 4.866 billion yuan [1]. - Year-to-date, the stock price has risen by 116.64%, with a 0.77% increase over the last five trading days, a 10.85% increase over the last 20 days, and a 106.45% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on August 19, where it recorded a net purchase of 16.15 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Shenlian Bio was 9,466, an increase of 6.46% from the previous period. The average circulating shares per person decreased by 6.06% to 43,380 shares [2]. Industry Classification - Shenlian Bio belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically in the animal health industry, and is associated with concepts such as small-cap stocks, pet economy, margin trading, vaccines, and biomedicine [2].

申联生物于2019年10月28日在上海证券交易所科创板上市，发行数量5,000万股，发行价格8.80元/股， 保荐机构（主承销商）为国信证券股份有限公司，保荐代表人为吴风来、王攀。 上市首日，申联生物盘中最高价报36.88元，为该股上市以来最高价。 中国经济网北京9月11日讯 申联生物(688098.SH)近日发布2025年半年度报告。报告期内，该公司实现营 业收入1.22亿元，同比下降3.68%；实现归属于上市公司股东的净利润-1286.97万元，上年同期 为-3450.80万元；实现归属于上市公司股东的扣除非经常性损益的净利润-1679.62万元，上年同期 为-3544.40万元；经营活动产生的现金流量净额为-3938.91万元，上年同期为-80.56万元。 2024年，申联生物实现营业收入30,341.47万元，同比增长0.64%；实现归属于上市公司股东的净利 润-4,474.01万元，上年同期为3,151.87万元；实现归属于上市公司股东的扣除非经常性损益的净利 润-4,837.65万元，上年同期为2,506.98万元；经营活动产生的现金流量净额为8,936.20万元，上年同期为 352.55万元。 ...

Market Overview - The animal health sector experienced a decline of 0.5% on September 10, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.21, up 2.75% [1] - *ST Lvkang (002868) at 26.42, up 1.62% [1] - Houfeng Holdings (002141) at 4.00, up 0.76% [1] - Major decliners included: - Yongshun Biological (839729) at 10.62, down 3.28% [2] - Shilian Biological (688098) at 11.72, down 1.76% [2] - Huai Sheng Biological (300871) at 22.20, down 1.60% [2] Capital Flow Analysis - The animal health sector saw a net outflow of 81.6 million yuan from institutional investors, while retail investors contributed a net inflow of 53.0 million yuan [2] - The detailed capital flow for key stocks showed: - Repu Biological (300119) had a net inflow of 1.12 million yuan from retail investors [3] - Kexian Biological (688526) saw a net inflow of 14.78 thousand yuan from institutional investors [3] - Hai Li Biological (603718) experienced a significant net outflow of 22.66 million yuan from institutional investors [3]

Core Viewpoint - Shenyuan Biological has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China to produce a dual inactivated vaccine for swine, targeting both Streptococcus suis disease and infectious pleuropneumonia [1] Group 1 - The approved vaccine is specifically for the prevention of infectious pleuropneumonia and Streptococcus suis disease in pigs [1] - The vaccine combines two strains: ZY-2 strain (type 2) and SC strain (type 1) [1] - The approval is in accordance with the Veterinary Drug Management Regulations and the Management Measures for the Approval Numbers of Veterinary Drug Products [1]

证券代码：688098 证券简称：申联生物 公告编号：2025-035 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》《兽药产品批准文号管理办法》等有关规定，经中华 人民共和国农业农村部审查，准予申联生物医药（上海）股份有限公司兰州分 公司生产猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2型ZY-2株+1型SC株）， 并核发兽药产品批准文号批件，具体情况如下： 一、兽药产品批准文号基本情况 1、通用名称：猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2型ZY-2株+1型SC 株） 2、兽药产品批准文号：兽药生字280181168 3、商品名称：传联清 4、有效期：2025年9月3日至2030年9月2日 二、兽药产品及其市场情况 猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2 型 ZY-2 株+1 型 SC 株）用于 预防猪传染性胸膜肺炎和猪链球菌病。猪链球菌病是由猪链球菌引起的细菌性传 染病，主要引起猪的败血症、脑膜炎和关节炎等临床症状；传染性胸膜肺炎是由胸 膜肺炎放线杆菌引起的一种高度接触性呼吸道传染病，其病理特征是纤 ...

申联生物(688098.SH)发布公告，根据《兽药管理条例》《兽药产品批准文号管理办法》等有关规定， 经中华人民共和国农业农村部审查，准予申联生物医药(上海)股份有限公司兰州分公司生产猪链球菌 病、传染性胸膜肺炎二联灭活疫苗(2型ZY-2株+1型SC株)，并核发兽药产品批准文号批件。 该产品的获批及上市将进一步完善公司兽用细菌病防控产品矩阵，产品将在公司已有的细菌灭活疫苗 GMP生产线上生产，将有助于提升产能利用率，为客户提供更全面、高效的疫病防控解决方案。 ...

该产品的获批及上市将进一步完善公司兽用细菌病防控产品矩阵，产品将在公司已有的细菌灭活疫苗 GMP生产线上生产，将有助于提升产能利用率，为客户提供更全面、高效的疫病防控解决方案。 智通财经APP讯，申联生物(688098.SH)发布公告，根据《兽药管理条例》《兽药产品批准文号管理办 法》等有关规定，经中华人民共和国农业农村部审查，准予申联生物医药(上海)股份有限公司兰州分公 司生产猪链球菌病、传染性胸膜肺炎二联灭活疫苗(2型ZY-2株+1型SC株)，并核发兽药产品批准文号批 件。 ...

人民财讯9月8日电，申联生物(688098)9月8日晚间公告，经中华人民共和国农业农村部审查，准予申联 生物医药(上海)股份有限公司兰州分公司生产猪链球菌病、传染性胸膜肺炎二联灭活疫苗(2型ZY-2株+1 型SC株)，并核发兽药产品批准文号批件。 ...